PAR

Par Drugs And Chemicals Limited

· Unclassified
₹ CrorePeersBALAXICROWNSTEELCITYHINDCONLATTEYSHECPROJECTAIROLAMGROBTEA
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity16.9313.5011.7111.71
Return on Assets14.2711.1910.1510.15
Return on Capital Employed21.7315.4211.6311.63
Return on Invested Capital29.4016.5514.5117.46
Margins
EBITDA Margin23.8619.3116.5318.32
Operating Margin20.2615.7012.9512.95
Incremental Operating Margin-66.13-90.47
Pretax Margin20.4117.7516.6917.59
Net Income Margin15.1613.2312.6513.31
FCF Margin14.8114.7613.9613.96
Additional
Effective Tax Rate25.7025.4724.2324.33
Sustainable Growth Rate16.9313.5011.7111.71
Incremental Operating Margin %-66.13-90.4752.71
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.